A Canadian pharmaceutical company is partnering with Harvard University and Brigham and Women’s Hospital to develop an oral drug that blocks the Ebola virus and could be tested on humans as early as this year. James Cunningham, associate professor of medicine at Brigham and Women’s, is the lead researcher on the project.
Trending News
Search for Babesiosis Treatment Gets a New Map
New clues to help fight tick-borne disease
Can an AI ‘Co-Scientist’ Accelerate Cancer Research?
Nearly $7 million funds agentic AI tools to assist investigations into cancer’s most pressing…
First Large-Scale Study Shows How Doctors Use AI in Medicine
Which practitioners use artificial intelligence in the clinic, and what do they ask?